Opdivo Archives -

Bristol-Myers Squibb has revealed that its checkpoint inhibitor combination of Opdivo and Yervoy failed a phase 3 trial

BMS’ plan to move Opdivo into adjuvant RCC gets knocked back

https://pharmaphorum.com/news/bms-plan-to-move-opdivo-into-adjuvant-rcc-gets-knocked-back/

BMS’ Opdivo gets NHS use as adjuvant bladder cancer therapy

Phil Taylor access, Bristol-Myers Squibb, HEOR, NHS, NICE, Opdivo, UK, urothelial carcinoma 0 Comment

NICE has recommended routine use of Bristol-Myers Squibb’s Opdivo for the adjuvant treatment of some patients with urothelial

BMS’ Opdivo gets NHS use as adjuvant bladder cancer therapy

https://pharmaphorum.com/news/bms-opdivo-gets-nhs-use-as-adjuvant-bladder-cancer-therapy/

News/ News/ News/ Oncology/ R&D

Novartis eyes earlier use of PD-1 drug in oesophageal cancer

Phil Taylor BeiGene, Bristol-Myers Squibb, immuno-oncology, Keytruda, Merck & Co, Novartis, oesophageal cancer, Oncology, Opdivo, tislelizumab 0 Comment

Novartis is still waiting for FDA approval of its PD-1/PD-L1 inhibitor latecomer tislelizumab in relapsed oesophageal cancer, but

Novartis eyes earlier use of PD-1 drug in oesophageal cancer

https://pharmaphorum.com/oncology/novartis-eyes-earlier-use-of-pd-1-drug-in-oesophageal-cancer/

News/ News/ News/ Oncology/ R&D

AZ takes aim at BMS’ lead in neoadjuvant NSCLC

Phil Taylor AstraZeneca, Bristol-Myers Squibb, Imfinzi, immuno-oncology, Keytruda, Merck & Co, Non-small cell lung cancer, Oncology, Opdivo 0 Comment

Just weeks after Bristol-Myers Squibb claimed an FDA green light for Opdivo as a neoadjuvant therapy for non-small

AZ takes aim at BMS’ lead in neoadjuvant NSCLC

https://pharmaphorum.com/news/az-takes-aim-at-bms-lead-in-neoadjuvant-nsclc/

News/ News/ Oncology

BMS’ Opdivo gets late-stage oesophageal cancer nod from FDA

Phil Taylor Bristol-Myers Squibb, immuno-oncology, Keytruda, Merck & Co, oesophageal cancer, Oncology, Opdivo, regulatory approval 0 Comment

The FDA has cleared two combination drug regimens based on Bristol-Myers Squibb’s PD-1 inhibitor Opdivo for previously-untreated advanced

BMS’ Opdivo gets late-stage oesophageal cancer nod from FDA

https://pharmaphorum.com/news/bms-opdivo-gets-late-stage-oesophageal-cancer-nod-from-fda/

News/ News/ Oncology

BMS doubles down on BridgeBio alliance on SHP2 drugs

Phil Taylor BridgeBio Pharma, Bristol-Myers Squibb, immuno-oncology, Oncology, Opdivo, partnering, SHP2 0 Comment

Bristol-Myers Squibb’s flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting

BMS doubles down on BridgeBio alliance on SHP2 drugs

https://pharmaphorum.com/news/bms-doubles-down-on-bridgebio-alliance-on-shp2-drugs/

News/ News/ Oncology

BMS gets FDA OK for first LAG-3 checkpoint inhibitor

Phil Taylor Bristol-Myers Squibb, favezelimab, LAG-3, Merck & Co, Opdivo, Opdualag, regulatory approval, relatlimab 0 Comment

Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer

BMS gets FDA OK for first LAG-3 checkpoint inhibitor

https://pharmaphorum.com/news/bms-gets-fda-ok-for-first-lag-3-checkpoint-inhibitor/

News/ News/ Oncology

BMS carves out a neoadjuvant niche for Opdivo in NSCLC

Phil Taylor Bristol-Myers Squibb, Keytruda, Merck & Co, Non-small cell lung cancer, Opdivo, Roche, Tecentriq 0 Comment

Bristol-Myers Squibb’s Opdivo has been playing second fiddle to Merck & Co’s Keytruda in the non-small cell lung

BMS carves out a neoadjuvant niche for Opdivo in NSCLC

https://pharmaphorum.com/news/bms-carves-out-a-neoadjuvant-niche-for-opdivo-in-nsclc/

News/ News/ Oncology

Opdivo and chemotherapy combo increases survival in lung cancer patients

Joy Persaud lung cancer, Opdivo 0 Comment

Lung cancer drug Opdivo administered with chemotherapy has been shown to boost survival rates in patients with resectable

Opdivo and chemotherapy combo increases survival in lung cancer patients

https://pharmaphorum.com/news/opdivo-chemotherapy-combo-increases-survival-lung-cancer-patients/

Trending

Opdivo

Login